Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM
Ahmad Masri, Cardiomyopathy Section Head at Oregon Health and Science University, shared a post on LinkedIn about a recent article by Peter C. Kahr et al., published in Nature Medicine, adding:
“Longer term data from the cliramitug depleter program in ATTR-CM.
- The furthest along in development from this new class of drugs in ATTR.
- Cliramitug – phase III ongoing.
- Coramitug – enrolling now in phase III.
- AT02 – phase I-II.
2 new depleters in the preclinical settings – one from BridgeBio and one from Immutrin.”
Title: Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial
Authors: Peter C. Kahr, Fabian aus dem Siepen, Olivier Lairez, Erwan Donal, Thibaud Damy, Arnt V. Kristen, Cristina C. Quarta, Michele F. Mercuri, Sarah Keppner-Witter, Eva Herrmann-Keiner, Mia Tichy, Aubin Michalon, Jan Grimm, Roger M. Nitsch, Christoph Hock, Pablo Garcia-Pavia, Peter van der Meer
Stay updated with Hemostasis Today.
-
Oct 10, 2026, 17:58Archo Farzana Batool: Exploring Medical Writing Through an Article on Iron Deficiency Anemia
-
Oct 10, 2026, 17:53Assessing Frailty in Adults With Hemophilia – JTH
-
Oct 10, 2026, 17:52Fatma Sadeghi: Reducing Maternal Health Inequalities Through Nursing Advocacy
-
Oct 10, 2026, 17:50Grzegorz Hensler: How Apheresis Transformed Blood Cell Separation and Collection
-
Oct 10, 2026, 17:47Hemant K Sharma: Japan’s Universal Artificial Blood Research – A Potential Breakthrough in Transfusion Medicine
-
Oct 10, 2026, 17:40John Strouse: Learning About Bleeding Disorders and Sickle Cell Disease at FWGBD
-
Oct 10, 2026, 17:34Mae Caime: Speaking at the Annual Women’s Retreat for the Hemophilia Community in Florida
-
Oct 10, 2026, 17:30Chokri Ben Lamine: PNH beyond the Textbook Triad
-
Oct 10, 2026, 17:29Ruah Alyamany: Thrombosis and Anticoagulation in Hematological Malignancies at SOHO KSA 2026